CytRx Corporation (CYTR)

0.35
0.03 9.34
OTC
Prev Close 0.32
Open 0.32
Day Low/High 0.32 / 0.35
52 Wk Low/High 0.26 / 1.29
Volume 35.12K
Exchange OTC
Shares Outstanding 33.64B
Market Cap 11.10M
Div & Yield N.A. (N.A)
CytRx Corporation (CYTR) Showing Signs Of A Dead Cat Bounce Today

CytRx Corporation (CYTR) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Galena Biopharma Pays For Stock-Touting Campaign While Insiders Cash Out Millions

Galena Biopharma Pays For Stock-Touting Campaign While Insiders Cash Out Millions

Seeking Alpha removes articles after finding single author used multiple aliases to promote Galena.

CytRx Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares

CytRx Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the closing of its previously announced underwritten public offering.

Trade-Ideas: CytRx Corporation (CYTR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: CytRx Corporation (CYTR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

CytRx To Present At The 16th Annual BIO CEO & Investor Conference On February 10, 2014, In New York City

CytRx To Present At The 16th Annual BIO CEO & Investor Conference On February 10, 2014, In New York City

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A.

CytRx Announces Pricing Of Approximately $75 Million Public Offering Of Common Stock

CytRx Announces Pricing Of Approximately $75 Million Public Offering Of Common Stock

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the pricing of its previously announced underwritten public offering.

CytRx Announces Proposed Public Offering Of Common Stock

CytRx Announces Proposed Public Offering Of Common Stock

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced its intention, subject to market and other conditions, to commence an underwritten...

Nothing to Gain from this Dangerous Tape

The best strategy now is to go into stalker mode and wait to pick up strong stocks at value prices.

Stock To Watch: CytRx Corporation (CYTR) In Perilous Reversal

Stock To Watch: CytRx Corporation (CYTR) In Perilous Reversal

Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "perilous reversal" (up big yesterday but down big today) candidate

3 Oncology Biotechs to Watch

3 Oncology Biotechs to Watch

Handicapping the potential of Galena Biopharma, CytRx and Northwest Biotherapeutics requires a solid understanding of what has been driving share prices.

5 Stocks Ready to Break Out

5 Stocks Ready to Break Out

These stocks look poised to break out and trade higher from current levels.

CytRx Initiates Phase 2 Clinical Trial With Aldoxorubicin For First-Line Treatment Of AIDS-Related Kaposi’s Sarcoma

CytRx Initiates Phase 2 Clinical Trial With Aldoxorubicin For First-Line Treatment Of AIDS-Related Kaposi’s Sarcoma

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and ...

CytRx Receives FDA Approval To Extend Aldoxorubicin Dosing Cycles Until Disease Progression In Upcoming Pivotal, Global Phase 3 Trial For Soft Tissue Sarcomas

CytRx Receives FDA Approval To Extend Aldoxorubicin Dosing Cycles Until Disease Progression In Upcoming Pivotal, Global Phase 3 Trial For Soft Tissue Sarcomas

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.

Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week

Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week

The drug companies on this list issued the most ridiculous, stock-touting press releases, all seeking to glom onto the excitement of the JPM healthcare conference.

Today's Dead Cat Bounce Stock: CytRx Corporation (CYTR)

Today's Dead Cat Bounce Stock: CytRx Corporation (CYTR)

Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

CytRx Appoints Shanta Chawla, M.D. As Vice President, Clinical Development

CytRx Appoints Shanta Chawla, M.D. As Vice President, Clinical Development

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the appointment of Shanta Chawla, M.

CytRx Corporation Doses First Patient In Phase 2 Clinical Trial With Aldoxorubicin For The Treatment Of Unresectable Glioblastoma Multiforme (Brain Cancer)

CytRx Corporation Doses First Patient In Phase 2 Clinical Trial With Aldoxorubicin For The Treatment Of Unresectable Glioblastoma Multiforme (Brain Cancer)

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the first patient has been dosed in the Company’s Phase 2 clinical trial ...

CytRx Corporation (CYTR) In A Perilous Reversal

CytRx Corporation (CYTR) In A Perilous Reversal

Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "perilous reversal" (up big yesterday but down big today) candidate

CytRx Corporation (CYTR) Is Today's Dead Cat Bounce Stock

CytRx Corporation (CYTR) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

CytRx Reports Additional Analyses Supporting Highly Statistically Significant Positive Results From Global Phase 2b Clinical Trial With Aldoxorubicin In Advanced Soft Tissue Sarcomas

CytRx Reports Additional Analyses Supporting Highly Statistically Significant Positive Results From Global Phase 2b Clinical Trial With Aldoxorubicin In Advanced Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported positive results from additional statistical analyses that further support the ...

CytRx Corporation (CYTR) Showing Signs Of Perilous Reversal Today

CytRx Corporation (CYTR) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "perilous reversal" (up big yesterday but down big today) candidate

CytRx Corporation (CYTR) Marked As A Dead Cat Bounce Stock

CytRx Corporation (CYTR) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

A Classic Melt-Up

Hopeful bears were dead wrong again.

Trade-Ideas: CytRx Corporation (CYTR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: CytRx Corporation (CYTR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

CytRx Directors Are $3M Richer With Well-Timed Stock Option Grants

CytRx Directors Are $3M Richer With Well-Timed Stock Option Grants

CytRx directors award themselves stocks option one day before the company's stock prices soars on clinical trial results.

CytRx (CYTR) Soars on 2-Day Rally

CytRx (CYTR) Soars on 2-Day Rally

CytRx Corp. (CYTR) extended a rally through its second day, in stark contrast to ImmunoCellular Therapeutics' (IMUC) 60% fall on Thursday.

Perilous Reversal Watch: CytRx Corporation (CYTR)

Perilous Reversal Watch: CytRx Corporation (CYTR)

Trade-Ideas LLC identified CytRx Corporation (CYTR) as a "perilous reversal" (up big yesterday but down big today) candidate

Why CytRx (CYTR) Is Exploding on Wednesday

Why CytRx (CYTR) Is Exploding on Wednesday

CytRx (CYTR) has gained double-digits on Wednesday after the drugmaker announced positive developments.

CytRx Reports Highly Statistically Significant Positive Results From Its Global Phase 2b Clinical Trial

CytRx Reports Highly Statistically Significant Positive Results From Its Global Phase 2b Clinical Trial

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced highly positive top-line efficacy results from a multicenter, randomized, ...

CytRx To Hold Conference Call December 11, 2013 At 10:30 A.m. Eastern Time To Discuss Results Of Global Phase 2b Clinical Trial With Aldoxorubicin Versus Doxorubicin As First-Line Therapy In Advanced Soft Tissue Sarcomas

CytRx To Hold Conference Call December 11, 2013 At 10:30 A.m. Eastern Time To Discuss Results Of Global Phase 2b Clinical Trial With Aldoxorubicin Versus Doxorubicin As First-Line Therapy In Advanced Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will issue a news release at 8:00 a.

TheStreet Quant Rating: D- (Sell)